Bessemer Group’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$71K Sell
1,410
-18
-1% -$1.02K ﹤0.01% 1620
2026
Q2
$96K Hold
1,428
– – ﹤0.01% 1533
2026
Q1
$79K Sell
1,428
-33
-2% -$1.78K ﹤0.01% 1551
2025
Q4
$71K Buy
1,461
+33
+2% +$1.29K ﹤0.01% 1543
2025
Q3
$44K Buy
1,428
+1,292
+950% +$29.7K ﹤0.01% 1465
2025
Q2
$3K Buy
136
+110
+423% +$2.3K ﹤0.01% 2108
2025
Q1
$0 Buy
+26
New – ﹤0.01% 2428
2024
Q4
– Sell
-50
Closed -$2K – 2447
2024
Q3
$2K Buy
+50
New +$1.71K ﹤0.01% 2160

Other funds holding ANAB

Bessemer Group's ANAB Position: Q3 2026 in Review

Bessemer Group reduced its AnaptysBio (ANAB) stake by 1.3% in Q3 2026, selling an estimated $1.02K and leaving 1,410 shares worth $71K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

Bessemer Group first reported a position in ANAB in Q3 2024 and has held it in 8 quarters since. The position peaked at $96K in Q2 2026. 229 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

  • Bessemer Group held 1,410 shares of AnaptysBio worth $71K as of Q3 2026.
  • Bessemer Group sold 18 AnaptysBio shares in Q3 2026, an estimated $1.02K.
  • AnaptysBio made up ﹤0.01% of Bessemer Group's portfolio in Q3 2026, its #1620 holding.
  • Bessemer Group first reported a position in AnaptysBio in Q3 2024 and has held it in 8 quarters since.
  • Bessemer Group's AnaptysBio position peaked at $96K in Q2 2026.
  • 229 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on Bessemer Group's 13F filing for Q3 2026, filed 9 Nov 2026.